Paul C. Grint

Biography

Dr. Paul C. Grint, M.D., has been the Chief Executive Officer of AmpliPhi Biosciences Corporation since May 31, 2017. Dr. Grint served as the Chief Executive Officer and President of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017 and served as its Chief Medical Officer from June 16, 2014 to June 1, 2015.  He serves as a Director of Synedgen Inc. He serves as a Member of Advisory Board at CovX Research LLC. He served as a Director of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017. He served as Member of Scientific Advisory Board at MultiCell Technologies, Inc. He served as a Member of clinical Advisory Board of Tobira Therapeutics, Inc. Dr. Grint served as a Director of Illumina, Inc. from April 12, 2005 to May 29, 2013. He serves as Chairman of the Advisory Council of the Keck Graduate Institute. He served as the Chairman of the Biotechnology Therapy Team at St. Bartholomew's Hospital in London. He served as an Honorary Lecturer in the Department of Virology at St. Bartholomew's Hospital in London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies and the author or co-author of over fifty scientific publications. Dr. Grint received his Medical Degree from the University of London, St. Bartholomew's Hospital Medical College in London, U.K. He has a B.S. in Medical Science from Barts & The London School of Medicine & Dentistry, Queen Mary University of London.

Research Interest

Biomedicine,Biomedical Products